Lyle W Murray1,2, Iman Satti3, Jodi Meyerowitz1, Matthew Jones1, Christian B Willberg1,4, James E Ussher1,5, Dominique Goedhals6, Jacob Hurst1,7, Rodney E Phillips1,7, Helen McShane3, Cloete van Vuuren8, John Frater1,4,7. 1. Peter Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, United Kingdom. 2. Department of Internal Medicine, University of the Witwatersrand, Johannesburg, South Africa. 3. Jenner Institute, University of Oxford, United Kingdom. 4. Oxford National Institute of Health Research Biomedical Research Centre, United Kingdom. 5. Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand. 6. Department of Medical Microbiology and Virology, National Health Laboratory Service/University of the Free State, Bloemfontein, South Africa. 7. Oxford Martin School, Oxford, United Kingdom. 8. Division of Infectious Diseases, Department of Internal Medicine, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa.
Abstract
Background: Human immunodeficiency virus (HIV)-infected individuals have a higher risk of developing active tuberculosis (TB) than HIV-uninfected individuals, but the mechanisms underpinning this are unclear. We hypothesized that depletion of specific components of Mycobacterium tuberculosis (Mtb)-specific CD4+ and CD8+ T-cell responses contributed to this increased risk. Methods: Mtb-specific T-cell responses in 147 HIV-infected and 44 HIV-uninfected control subjects in a TB-endemic setting in Bloemfontein, South Africa, were evaluated. Using a whole-blood flow cytometry assay, we measured expression of interferon gamma, tumor necrosis factor alpha, interleukin 2, and interleukin 17 in CD4+ and CD8+ T cells in response to Mtb antigens (PPD, ESAT-6/CFP-10 [EC], and DosR regulon-encoded α-crystallin [Rv2031c]). Results: Fewer HIV-infected individuals had detectable CD4+ and CD8+ T-cell responses to PPD and Rv2031c than HIV-uninfected subjects. Mtb-specific T cells showed distinct patterns of cytokine expression comprising both Th1 (CD4 and CD8) and Th17 (CD4) cytokines, the latter at highest frequency for Rv2031c. Th17 antigen-specific responses to all antigens tested were specifically impaired in HIV-infected individuals. Conclusions: HIV-associated impairment of CD4+ and CD8+Mtb-specific T-cell responses is antigen specific, particularly impacting responses to PPD and Rv2031c. Preferential depletion of Th17 cytokine-expressing CD4+ T cells suggests this T-cell subset may be key to TB susceptibility in HIV-infected individuals.
Background: Human immunodeficiency virus (HIV)-infected individuals have a higher risk of developing active tuberculosis (TB) than HIV-uninfected individuals, but the mechanisms underpinning this are unclear. We hypothesized that depletion of specific components of Mycobacterium tuberculosis (Mtb)-specific CD4+ and CD8+ T-cell responses contributed to this increased risk. Methods: Mtb-specific T-cell responses in 147 HIV-infected and 44 HIV-uninfected control subjects in a TB-endemic setting in Bloemfontein, South Africa, were evaluated. Using a whole-blood flow cytometry assay, we measured expression of interferon gamma, tumor necrosis factor alpha, interleukin 2, and interleukin 17 in CD4+ and CD8+ T cells in response to Mtb antigens (PPD, ESAT-6/CFP-10 [EC], and DosR regulon-encoded α-crystallin [Rv2031c]). Results: Fewer HIV-infected individuals had detectable CD4+ and CD8+ T-cell responses to PPD and Rv2031c than HIV-uninfected subjects. Mtb-specific T cells showed distinct patterns of cytokine expression comprising both Th1 (CD4 and CD8) and Th17 (CD4) cytokines, the latter at highest frequency for Rv2031c. Th17 antigen-specific responses to all antigens tested were specifically impaired in HIV-infected individuals. Conclusions: HIV-associated impairment of CD4+ and CD8+Mtb-specific T-cell responses is antigen specific, particularly impacting responses to PPD and Rv2031c. Preferential depletion of Th17 cytokine-expressing CD4+ T cells suggests this T-cell subset may be key to TB susceptibility in HIV-infected individuals.
Authors: Deborah A Lewinsohn; Amy S Heinzel; James M Gardner; Liqing Zhu; Mark R Alderson; David M Lewinsohn Journal: Am J Respir Crit Care Med Date: 2003-09-11 Impact factor: 21.405
Authors: K V Komanduri; S M Donahoe; W J Moretto; D K Schmidt; G Gillespie; G S Ogg; M Roederer; D F Nixon; J M McCune Journal: Virology Date: 2001-01-20 Impact factor: 3.616
Authors: Andrew Prendergast; Julia G Prado; Yu-Hoi Kang; Fabian Chen; Lynn A Riddell; Graz Luzzi; Philip Goulder; Paul Klenerman Journal: AIDS Date: 2010-02-20 Impact factor: 4.177
Authors: Cheryl L Day; Deborah A Abrahams; Levelle D Harris; Michele van Rooyen; Lynnett Stone; Marwou de Kock; Willem A Hanekom Journal: J Immunol Date: 2017-07-31 Impact factor: 5.422
Authors: Christof Geldmacher; Alexandra Schuetz; Njabulo Ngwenyama; Joseph P Casazza; Erica Sanga; Elmar Saathoff; Catharina Boehme; Steffen Geis; Leonard Maboko; Mahavir Singh; Fred Minja; Andreas Meyerhans; Richard A Koup; Michael Hoelscher Journal: J Infect Dis Date: 2008-12-01 Impact factor: 5.226
Authors: Crystal Y Chen; Dan Huang; Richard C Wang; Ling Shen; Gucheng Zeng; Shuyun Yao; Yun Shen; Lisa Halliday; Jeff Fortman; Milton McAllister; Jim Estep; Robert Hunt; Daphne Vasconcelos; George Du; Steven A Porcelli; Michelle H Larsen; William R Jacobs; Barton F Haynes; Norman L Letvin; Zheng W Chen Journal: PLoS Pathog Date: 2009-04-17 Impact factor: 6.823
Authors: Barbara Kalsdorf; Thomas J Scriba; Kathryn Wood; Cheryl L Day; Keertan Dheda; Rodney Dawson; Willem A Hanekom; Christoph Lange; Robert J Wilkinson Journal: Am J Respir Crit Care Med Date: 2009-09-24 Impact factor: 21.405
Authors: Rubina Bunjun; Fidilia M A Omondi; Mohau S Makatsa; Roanne Keeton; Jerome M Wendoh; Tracey L Müller; Caryn S L Prentice; Robert J Wilkinson; Catherine Riou; Wendy A Burgers Journal: J Immunol Date: 2021-08-13 Impact factor: 5.422
Authors: Beatriz Barreto-Duarte; Timothy R Sterling; Christina T Fiske; Alexandre Almeida; Cynthia H Nochowicz; Rita M Smith; Louise Barnett; Christian Warren; Amondrea Blackman; Jose Roberto Lapa E Silva; Bruno B Andrade; Spyros A Kalams Journal: Front Immunol Date: 2020-12-17 Impact factor: 7.561
Authors: Collin R Diedrich; Tara Rutledge; Pauline Maiello; Tonilynn M Baranowski; Alexander G White; H Jacob Borish; Paul Karell; Forrest Hopkins; Jessica Brown; Sarah M Fortune; JoAnne L Flynn; Zandrea Ambrose; Philana Ling Lin Journal: PLoS Pathog Date: 2020-07-30 Impact factor: 6.823
Authors: Chansavath Phetsouphanh; Daniel Aldridge; Emanuele Marchi; C Mee Ling Munier; Jodi Meyerowitz; Lyle Murray; Cloete Van Vuuren; Dominique Goedhals; Sarah Fidler; Anthony Kelleher; Paul Klenerman; John Frater Journal: Front Immunol Date: 2019-08-08 Impact factor: 7.561
Authors: Matthew B Huante; Tais B Saito; Rebecca J Nusbaum; Kubra F Naqvi; Sadhana Chauhan; Robert L Hunter; Jeffrey K Actor; Jai S Rudra; Mark A Endsley; Joshua G Lisinicchia; Benjamin B Gelman; Janice J Endsley Journal: Front Cell Infect Microbiol Date: 2020-04-16 Impact factor: 5.293
Authors: Morgan S Barham; Wendy E Whatney; Jeremiah Khayumbi; Joshua Ongalo; Loren E Sasser; Angela Campbell; Meghan Franczek; Mbuyi Madeleine Kabongo; Samuel G Ouma; Felix Odhiambo Hayara; Neel R Gandhi; Cheryl L Day Journal: Immunohorizons Date: 2020-10-02